Details of the Drug Transporter (DTP)

General Information of Drug Transporter (DTP) (ID: DT9JBVI)

DTP Name Sodium-dependent noradrenaline transporter (SLC6A2)
Gene Name SLC6A2
UniProt ID
P23975 (SC6A2_HUMAN)
VARIDT ID
DTD0452
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Synonyms NET; NET1; Norepinephrine transporter; SLC6A2; Solute carrier family 6 member 2
DTP Family Neurotransmitter:Sodium Symporter (NSS) Family ;
Sequence
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
VAQRDIRQFQLQHWLAI
Function This transporter is amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Endogenous Substrate(s) 1-methyl-4-tetrahydropyridinium; Na+
TCDB ID
2.A.22.1.2
Gene ID
6530
KEGG Pathway
Synaptic vesicle cycle (hsa04721 )
Reactome Pathway
Defective SLC6A2 causes orthostatic intolerance (OI) (R-HSA-5619109 )
Na+/Cl- dependent neurotransmitter transporters (R-HSA-442660 )

Molecular Interaction Atlas (MIA) of This DTP

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTP
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amphetamine DMSZQAK Attention deficit hyperactivity disorder 6A05.Z Approved [98]
Norepinephrine DMOUC09 Alopecia ED70 Approved [99]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTP

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTP
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 4.12E-02 3.12E-02 2.02E-01
Adrenocortical carcinoma 2D11.Z Kidney 9.38E-01 -1.07E-01 -1.97E-01
Alopecia ED70 Skin from scalp 8.56E-01 1.56E-02 3.87E-02
Alzheimer's disease 8A20 Entorhinal cortex 2.23E-01 -3.04E-02 -2.17E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 7.30E-01 3.68E-02 3.57E-01
Aortic stenosis BB70 Calcified aortic valve 4.50E-01 -8.05E-02 -4.67E-01
Apnea 7A40 Hyperplastic tonsil 9.38E-02 1.55E-01 9.47E-01
Arthropathy FA00-FA5Z Peripheral blood 4.80E-01 4.94E-02 5.02E-01
Asthma CA23 Nasal and bronchial airway 4.78E-01 -2.85E-03 -1.52E-02
Atopic dermatitis EA80 Skin 6.45E-01 2.14E-01 4.48E-01
Autism 6A02 Whole blood 1.12E-01 -1.11E-01 -6.19E-01
Autoimmune uveitis 9A96 Peripheral monocyte 1.20E-01 -1.57E-01 -1.47E+00
Autosomal dominant monocytopenia 4B04 Whole blood 2.31E-01 3.23E-02 3.11E-01
Bacterial infection of gingival 1C1H Gingival tissue 8.02E-01 -2.75E-02 -1.49E-01
Batten disease 5C56.1 Whole blood 9.88E-01 2.71E-02 6.40E-01
Behcet's disease 4A62 Peripheral blood 2.06E-01 5.06E-02 3.38E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 3.98E-01 -1.83E-02 -1.68E-01
Bladder cancer 2C94 Bladder tissue 2.33E-02 2.39E-01 1.15E+00
Breast cancer 2C60-2C6Z Breast tissue 1.01E-26 -2.00E-01 -1.04E+00
Cardioembolic stroke 8B11.20 Whole blood 2.73E-02 1.24E-01 8.23E-01
Cervical cancer 2C77 Cervical tissue 5.72E-01 7.88E-03 4.13E-02
Childhood onset rheumatic disease FA20.Z Peripheral blood 3.82E-01 -2.03E-02 -1.12E-01
Chronic hepatitis C 1E51.1 Whole blood 7.46E-01 -2.93E-02 -2.25E-01
Chronic obstructive pulmonary disease CA22 Lung tissue 1.20E-02 9.98E-02 8.19E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 1.24E-02 4.39E-02 3.90E-01
Chronic rhinosinusitis CA0A Sinus mucosa tissue 4.40E-02 -5.75E-02 -8.35E-01
Colon cancer 2B90 Colon tissue 7.77E-02 4.50E-02 2.55E-01
Coronary artery disease BA80-BA8Z Peripheral blood 2.17E-01 -1.85E-01 -1.01E+00
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 9.37E-01 -1.12E-02 -6.49E-02
Endometriosis GA10 Endometrium tissue 1.87E-01 4.90E-02 2.80E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 1.66E-01 -5.16E-02 -3.86E-01
Familial hypercholesterolemia 5C80.00 Whole blood 1.18E-03 -1.85E-01 -6.93E-01
Gastric cancer 2B72 Gastric tissue 5.63E-01 4.01E-02 1.48E-01
Glioblastopma 2A00.00 Nervous tissue 4.79E-01 3.45E-02 1.32E-01
Glioma 2A00.0Y-2A00.0Z White matter tissue 9.93E-05 -3.86E-01 -2.76E+00
Head and neck cancer 2D42 Head and neck tissue 1.69E-09 1.56E-01 8.85E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 1.30E-01 -6.26E-02 -5.58E-01
Huntington's disease 8A01.10 Whole blood 3.82E-01 8.90E-02 6.37E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 2.30E-01 2.67E-02 2.12E-01
Immunodeficiency 4A00-4A20 Peripheral blood 4.46E-01 2.26E-02 2.78E-01
Influenza 1.00E+30 Whole blood 1.65E-02 1.20E-01 4.16E+00
Interstitial cystitis GC00.3 Bladder tissue 5.55E-01 -5.25E-02 -3.81E-01
Intracranial aneurysm 8B01.0 Intracranial artery 1.67E-01 -7.35E-02 -7.49E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 9.38E-01 1.54E-02 5.86E-02
Ischemic stroke 8B11 Peripheral blood 1.61E-01 1.79E-02 2.11E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 8.47E-03 9.14E-02 5.68E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 1.43E-01 2.77E-02 2.72E-01
Lateral sclerosis 8B60.4 Skin 2.63E-01 1.07E-01 7.50E-01
Liver cancer 2C12.0 Liver tissue 1.59E-07 -8.38E-02 -4.21E-01
Liver failure DB99.7-DB99.8 Liver tissue 5.13E-01 6.51E-03 6.97E-02
Lung cancer 2C25 Lung tissue 9.64E-03 1.89E-02 1.36E-01
Lupus erythematosus 4A40 Whole blood 2.15E-02 -9.38E-02 -3.23E-01
Major depressive disorder 6A70-6A7Z Whole blood 1.77E-04 8.82E-02 5.73E-01
Major depressive disorder 6A70-6A7Z Hippocampus 7.05E-01 7.02E-03 6.74E-02
Melanoma 2C30 Skin 8.06E-04 -3.66E-01 -7.94E-01
Multiple myeloma 2A83.1 Bone marrow 5.04E-03 -2.18E-01 -1.16E+00
Multiple myeloma 2A83.1 Peripheral blood 6.60E-01 5.48E-02 4.57E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 4.95E-01 -1.42E-01 -6.39E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 1.83E-01 2.84E-02 1.84E-01
Myelofibrosis 2A20.2 Whole blood 5.04E-01 -8.23E-03 -7.43E-02
Myocardial infarction BA41-BA50 Peripheral blood 7.71E-02 2.82E-01 7.71E-01
Myopathy 8C70.6 Muscle tissue 4.85E-01 -6.26E-02 -2.80E-01
Neonatal sepsis KA60 Whole blood 6.53E-02 -5.41E-02 -2.50E-01
Neuroectodermal tumour 2A00.11 Brain stem tissue 2.69E-02 -2.70E-01 -7.80E-01
Non-alcoholic fatty liver disease DB92 Liver tissue 3.80E-01 -1.26E-01 -9.63E-01
Obesity related type 2 diabetes 5A11 Omental adipose tissue 8.19E-01 -1.96E-02 -1.83E-01
Olive pollen allergy CA08.00 Peripheral blood 6.67E-03 1.76E-01 2.27E+00
Oral cancer 2B6E Oral tissue 1.37E-04 7.41E-02 4.35E-01
Osteoarthritis FA00-FA0Z Synovial tissue 9.84E-01 -2.16E-02 -1.87E-01
Osteoporosis FB83.1 Bone marrow 2.73E-02 3.13E-01 3.13E+00
Ovarian cancer 2C73 Ovarian tissue 4.80E-01 -1.79E-01 -6.29E-01
Pancreatic cancer 2C10 Pancreas 1.58E-02 -1.46E-01 -5.11E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 6.13E-01 -2.15E-03 -1.04E-02
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 3.34E-01 -6.57E-02 -8.74E-01
Pituitary cancer 2D12 Pituitary tissue 1.23E-02 1.98E-01 8.54E-01
Pituitary gonadotrope tumour 2D12 Pituitary tissue 7.14E-01 3.06E-04 2.09E-03
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 5.98E-02 -5.70E-02 -6.88E-01
Polycythemia vera 2A20.4 Whole blood 9.15E-01 -3.52E-02 -3.35E-01
Pompe disease 5C51.3 Biceps muscle 7.58E-01 -2.56E-02 -2.34E-01
Preterm birth KA21.4Z Myometrium 2.28E-01 3.26E-02 2.90E-01
Prostate cancer 2C82 Prostate 2.25E-02 -1.11E-01 -2.52E-01
Psoriasis EA90 Skin 3.45E-01 -4.61E-02 -1.51E-01
Rectal cancer 2B92 Rectal colon tissue 3.31E-01 -5.64E-02 -2.24E-01
Renal cancer 2C90-2C91 Kidney 1.59E-01 -2.21E-01 -8.74E-01
Retinoblastoma 2D02.2 Uvea 6.67E-01 3.72E-02 4.91E-01
Rheumatoid arthritis FA20 Synovial tissue 3.38E-01 -1.73E-01 -6.82E-01
Rhinovirus infection CA42.1 Nasal epithelium tissue 2.62E-01 2.63E-02 2.56E-01
Schizophrenia 6A20 Prefrontal cortex 2.09E-02 8.44E-02 4.74E-01
Schizophrenia 6A20 Superior temporal cortex 8.32E-01 7.46E-03 9.05E-02
Scleroderma 4A42.Z Whole blood 4.09E-02 1.11E-01 9.85E-01
Seizure 8A60-8A6Z Whole blood 7.53E-01 1.83E-02 1.08E-01
Sensitive skin EK0Z Skin 3.01E-02 -2.72E-01 -1.70E+00
Sepsis with septic shock 1G41 Whole blood 6.23E-01 -1.34E-02 -6.55E-02
Shwachman-Diamond syndrome 3A70.0 Bone marrow 1.83E-02 5.24E-01 1.93E+00
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 1.13E-01 1.76E-02 2.26E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 6.13E-01 5.87E-02 8.46E-01
Sjogren's syndrome 4A43.2 Salivary gland tissue 3.34E-01 -1.07E-01 -5.12E-01
Skin cancer 2C30-2C3Z Skin 7.34E-22 -3.40E-01 -8.61E-01
Thrombocythemia 3B63 Whole blood 1.91E-01 -1.04E-01 -9.68E-01
Thrombocytopenia 3B64 Whole blood 7.91E-01 7.04E-02 6.15E-01
Thyroid cancer 2D10 Thyroid 3.29E-01 -1.62E-03 -1.19E-02
Tibial muscular dystrophy 8C75 Muscle tissue 4.71E-02 -9.54E-02 -5.49E-01
Tuberous sclerosis complex LD2D.2 Perituberal tissue 3.53E-01 1.00E-01 5.98E-01
Type 2 diabetes 5A11 Liver tissue 9.84E-01 8.71E-02 4.66E-01
Ureter cancer 2C92 Urothelium 1.85E-01 1.03E-01 9.00E-01
Uterine cancer 2C78 Endometrium tissue 5.18E-02 -6.02E-02 -3.11E-01
Vitiligo ED63.0 Skin 2.19E-01 4.51E-02 6.36E-02
------------------------------------------------------------------------------------
⏷ Show the Full List of Expression Under 107 Diseases

Drug Affinity of This DTP Assessed by Cell Line

Approved Drug(s)
Drug Name Highest Status Cell Line Affinity REF
Norepinephrine Approved Monkey kidney fibroblast-like cell (COS)1-NET Km = 690.0 microM [100]

The Drug Therapeutic Target (DTT) Role of This DTP

DTP DTT Name Norepinephrine transporter (NET) DTT Info
DTP DTT Type Successful
28 Approved Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [1]
Amfepramone DM9YSNQ Migraine 8A80 Approved [2]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [3]
Amoxapine DMKITQE Major depressive disorder 6A70.3 Approved [4]
Atomoxetine DM5L6HI Attention deficit hyperactivity disorder 6A05.Z Approved [5]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [6]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [7]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [8]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Desvenalfaxine succinate DMJE6KO Fibromyalgia MG30.01 Approved [9]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [10]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [11]
Iobenguane I-123 DM80OEZ Neuroendocrine cancer 2B72.1 Approved [12]
Levomilnacipran DMV26S8 Fibromyalgia MG30.01 Approved [13]
Maprotiline DMPWB7T Depression 6A70-6A7Z Approved [14]
Mazindol DMZ36RN Obesity 5B81 Approved [15]
Milnacipran DMBFE74 Depression 6A70-6A7Z Approved [16]
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [17]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [18]
Phentermine DMG60XN Obesity 5B81 Approved [19]
Protriptyline DMNHTZI Depression 6A70-6A7Z Approved [20]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [21]
Sibutramine DMFJTDI Obesity 5B81 Approved [22]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [23]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [24]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [6]
Hypericum DM8NWFD N. A. N. A. Phase 4 [25]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Approved Drug(s)
15 Clinical Trial Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [12]
Bicifadine DM42GP9 Chronic low back pain MG30.02 Phase 3 [27]
Roclatan DMVQ5X1 Glaucoma/ocular hypertension 9C61 Phase 3 [28]
Suronacrine maleate DMH2FN1 Cognitive impairment 6D71 Phase 3 [29]
18F-LMI-1195 DM8JVIB Heart failure BD10-BD13 Phase 2 [30]
BLI-1005 DMYK1DR Major depressive disorder 6A70.3 Phase 2 [26]
MCT-125 DMDR2SZ Fatigue MG22 Phase 2 [12]
Metaiodobenzylguanidine I-131 DMNST69 Neuroblastoma 2D11.2 Phase 2 [31]
NS 2359 DMI5HFU Cocaine addiction 6C45.2 Phase 2 [32]
PDC-1421 DMGP9VN Attention deficit hyperactivity disorder 6A05.Z Phase 2 [33]
Spiroglumide DM7NJWY Stomach disease DA43-DA4Y Phase 2 [34]
TD-9855 DMQD5NA Pain MG30-MG3Z Phase 2 [35]
XEN-2174 DM0NFMS Cancer related pain MG30 Phase 2 [36]
BL-1021 DMAYSFK Pain MG30-MG3Z Phase 1 [37]
GSK-1360707 DMZC9XU Major depressive disorder 6A70.3 Phase 1 [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Clinical Trial Drug(s)
10 Discontinued Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
DOV-216303 DMTE14H Mood disorder 6A60-6E23 Discontinued in Phase 2 [32]
Esreboxetine DMTUHWM Fibromyalgia MG30.01 Discontinued in Phase 2 [39]
Manifaxine DMRN7GC Major depressive disorder 6A70.3 Discontinued in Phase 2 [40]
Napitane mesilate DMF9Y57 Major depressive disorder 6A70.3 Discontinued in Phase 2 [41]
NS-2389 DMVRJ8D Major depressive disorder 6A70.3 Discontinued in Phase 2 [42]
R-sibutramine metabolite DMPAH74 Attention deficit hyperactivity disorder 6A05.Z Discontinued in Phase 2 [43]
Radafaxine DMARQE0 Major depressive disorder 6A70.3 Discontinued in Phase 2 [44]
SPD-473 DMTJNRL Mood disorder 6A60-6E23 Discontinued in Phase 2 [45]
NSD-644 DMNL9DS Neurological disorder 6B60 Discontinued in Phase 1 [46]
RG-7166 DMKLPMW Major depressive disorder 6A70.3 Discontinued in Phase 1 [47]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Discontinued Drug(s)
173 Investigative Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine DM2TIU3 Discovery agent N.A. Investigative [48]
(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine DML68KX Discovery agent N.A. Investigative [49]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R Discovery agent N.A. Investigative [50]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS Discovery agent N.A. Investigative [50]
(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol DMBXRKS Discovery agent N.A. Investigative [51]
(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM74IWX Discovery agent N.A. Investigative [52]
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM94B12 Discovery agent N.A. Investigative [49]
(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile DM134UV Discovery agent N.A. Investigative [49]
(R)-DULOXETINE DMECK7H Discovery agent N.A. Investigative [53]
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMJFH97 Discovery agent N.A. Investigative [54]
(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide DMQIUOB Discovery agent N.A. Investigative [54]
(R)-Norfluoxetine DMS30KU Discovery agent N.A. Investigative [55]
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM5ILK1 Discovery agent N.A. Investigative [49]
(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile DM32PJ5 Discovery agent N.A. Investigative [49]
(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMUAYZJ Discovery agent N.A. Investigative [54]
(S)-NORDULOXETINE DMULFYA Discovery agent N.A. Investigative [53]
(S)-Norfluoxetine DM8ZTPF Discovery agent N.A. Investigative [55]
1-(1,2-diphenylethyl)piperazine DM0ARKB Discovery agent N.A. Investigative [56]
1-(1,4-diphenylbutan-2-yl)piperazine DM8Z1QU Discovery agent N.A. Investigative [57]
1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMCSOAV Discovery agent N.A. Investigative [52]
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMS9PZ7 Discovery agent N.A. Investigative [52]
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine DM54ZKU Discovery agent N.A. Investigative [52]
1-(1-phenyl-2-o-tolylethyl)piperazine DMZ6QX0 Discovery agent N.A. Investigative [56]
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine DM0URSE Discovery agent N.A. Investigative [58]
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine DMJXKOF Discovery agent N.A. Investigative [59]
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMUJ2WB Discovery agent N.A. Investigative [52]
1-(2-(2-bromophenyl)-1-phenylethyl)piperazine DMPRALC Discovery agent N.A. Investigative [56]
1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine DM9CVX5 Discovery agent N.A. Investigative [60]
1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine DMUM4YQ Discovery agent N.A. Investigative [56]
1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine DMBRS3D Discovery agent N.A. Investigative [56]
1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine DMKWRCD Discovery agent N.A. Investigative [56]
1-(2-(2-fluorobenzyloxy)phenyl)piperazine DM6XCPV Discovery agent N.A. Investigative [59]
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine DM2H38V Discovery agent N.A. Investigative [52]
1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine DM4WEGM Discovery agent N.A. Investigative [56]
1-(2-(3-fluorophenoxy)phenyl)piperazine DMXV2KQ Discovery agent N.A. Investigative [59]
1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine DM8V5IH Discovery agent N.A. Investigative [56]
1-(2-(4-fluorophenoxy)phenyl)piperazine DMU082P Discovery agent N.A. Investigative [59]
1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine DMR4DJ1 Discovery agent N.A. Investigative [49]
1-(2-(benzyloxy)phenyl)piperazine DM0UZHL Discovery agent N.A. Investigative [59]
1-(2-(phenoxymethyl)phenyl)piperazine DM7Z19T Discovery agent N.A. Investigative [59]
1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBWCOZ Discovery agent N.A. Investigative [61]
1-(2-phenoxyphenyl)piperazine DMWFCYN Discovery agent N.A. Investigative [59]
1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol DMN4JU0 Discovery agent N.A. Investigative [62]
1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol DMWIEDN Discovery agent N.A. Investigative [62]
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one DM2SEXH Discovery agent N.A. Investigative [63]
1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one DMFYJ5V Discovery agent N.A. Investigative [63]
1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one DMPOVUY Discovery agent N.A. Investigative [63]
1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPEZ1V Discovery agent N.A. Investigative [61]
1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMB9T6F Discovery agent N.A. Investigative [61]
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one DMW6YDK Discovery agent N.A. Investigative [63]
1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPLEC0 Discovery agent N.A. Investigative [61]
1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one DM6ARQF Discovery agent N.A. Investigative [61]
1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBV8PT Discovery agent N.A. Investigative [61]
1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one DME435S Discovery agent N.A. Investigative [61]
1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one DMU04ZQ Discovery agent N.A. Investigative [61]
1S,2R-milnacipran DM7Y5AN Discovery agent N.A. Investigative [64]
2-((2-iodophenoxy)(phenyl)methyl)morpholine DMS1AOK Discovery agent N.A. Investigative [65]
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine DMS21CR Discovery agent N.A. Investigative [65]
2-(2'-Aminoethyl)-5-benzyltetrahydrofuran DMVTD1F Discovery agent N.A. Investigative [66]
2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine DM56NK4 Discovery agent N.A. Investigative [58]
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine DM1ULEX Discovery agent N.A. Investigative [60]
2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine DM1SN37 Discovery agent N.A. Investigative [60]
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine DMYVDJQ Discovery agent N.A. Investigative [60]
2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile DMO9SP1 Discovery agent N.A. Investigative [56]
2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran DMU4MIC Discovery agent N.A. Investigative [66]
2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran DMCUTY9 Discovery agent N.A. Investigative [66]
2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran DM157SO Discovery agent N.A. Investigative [66]
2-(Aminomethyl)-5-phenethyltetrahydrofuran DMEZ7O2 Discovery agent N.A. Investigative [66]
2-(N,N-Diethylamino)-3'-chloropropiophenone DMVR248 Discovery agent N.A. Investigative [67]
2-(N-Cyclopentylamino)-3'-bromopropiophenone DML4GHA Discovery agent N.A. Investigative [63]
2-(N-Cyclopentylamino)-3'-chloropropiophenone DMP68CE Discovery agent N.A. Investigative [67]
2-(N-Cyclopentylamino)-3'-fluoropropiophenone DMH6FKX Discovery agent N.A. Investigative [63]
2-(N-Cyclopentylamino)-3'-methoxypropiophenone DMVN1UI Discovery agent N.A. Investigative [63]
2-(N-Cyclopentylamino)-3'-methylpropiophenone DMG87RK Discovery agent N.A. Investigative [63]
2-(N-Cyclopropylamino)-3-chloropropiophenone DMNMES3 Discovery agent N.A. Investigative [67]
2-(N-Pyrrolidinyl)-3'-bromopropiophenone DM85ZCW Discovery agent N.A. Investigative [63]
2-(N-Pyrrolidinyl)-3'-fluoropropiophenone DMYPOC5 Discovery agent N.A. Investigative [63]
2-(N-Pyrrolidinyl)-3'-methoxypropiophenone DM1W3L9 Discovery agent N.A. Investigative [63]
2-(N-Pyrrolidinyl)-3'-methylpropiophenone DMGKXOI Discovery agent N.A. Investigative [63]
2-(N-Pyrrolidinyl)-3'-nitropropiophenone DM1I9LQ Discovery agent N.A. Investigative [63]
2-(N-tert-Butylamino)-3',4'-dichloropropiophenone DMKIEVP Discovery agent N.A. Investigative [67]
2-(N-tert-Butylamino)-3'-chloroheptanophenone DMY2PBO Discovery agent N.A. Investigative [67]
2-(N-tert-Butylamino)-3'-chlorohexanophenone DMPO3CJ Discovery agent N.A. Investigative [67]
2-(N-tert-Butylamino)-3'-chlorooctanophenone DMW47VA Discovery agent N.A. Investigative [67]
2-(N-tert-Butylamino)-3'-chloropentanophenone DMTZ540 Discovery agent N.A. Investigative [67]
2-(N-tert-Butylamino)propiophenone DM9E5LT Discovery agent N.A. Investigative [67]
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one DMI457Y Discovery agent N.A. Investigative [63]
2-(tert-butylamino)-1-m-tolylpropan-1-one DM6PV4W Discovery agent N.A. Investigative [63]
2-(tert-butylamino)-1-p-tolylpropan-1-one DMYFQDT Discovery agent N.A. Investigative [63]
2-(tert-Butylamino)-3',4'-dichlorobutyrophenone DMOJK8Y Discovery agent N.A. Investigative [67]
2-(tert-Butylamino)-3',4'-dichloropentanophenone DMMUDQ7 Discovery agent N.A. Investigative [67]
2-Amino-1-(4-methylthiophenyl)propane DMJ2Z9G Discovery agent N.A. Investigative [68]
2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran DMCJUWK Discovery agent N.A. Investigative [66]
2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran DM3OTZY Discovery agent N.A. Investigative [66]
2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran DMDG8FL Discovery agent N.A. Investigative [66]
2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran DME4P7K Discovery agent N.A. Investigative [66]
2-Aminomethyl-5-(phenyl)tetrahydrofuran DM413ZB Discovery agent N.A. Investigative [66]
2-phenoxy-3-(piperidin-4-yl)pyridine DM6JNT5 Discovery agent N.A. Investigative [60]
2pyrrolidin-1-yl-1-phenylpentan-1-one DMBJXCF Discovery agent N.A. Investigative [61]
3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine DMLV80B Discovery agent N.A. Investigative [69]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile DM6YJOU Discovery agent N.A. Investigative [56]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM6QZTB Discovery agent N.A. Investigative [56]
3-(3'-furyl)-aniline DM7FQVC Discovery agent N.A. Investigative [70]
3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine DM2ETXB Discovery agent N.A. Investigative [60]
3-p-Tolyl-8-aza-bicyclo[3.2.1]octane DM0872E Discovery agent N.A. Investigative [71]
3alpha-(bis-chloro-phenylmethoxy)tropane DMBUZWQ Discovery agent N.A. Investigative [72]
4-((naphthalen-2-yloxy)methyl)piperidine DMIQHYZ Discovery agent N.A. Investigative [49]
4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine DM7Y1ZD Discovery agent N.A. Investigative [73]
4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine DMJ9CNA Discovery agent N.A. Investigative [59]
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine DM9UA0N Discovery agent N.A. Investigative [59]
4-(2-(2-fluorobenzyloxy)phenyl)piperidine DMCR3VM Discovery agent N.A. Investigative [59]
4-(2-(3-chlorophenoxy)phenyl)piperidine DM0IT5E Discovery agent N.A. Investigative [59]
4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine DMEPB9L Discovery agent N.A. Investigative [59]
4-(2-(3-fluorophenoxy)phenyl)piperidine DMZMEOG Discovery agent N.A. Investigative [59]
4-(2-(4-fluorobenzyloxy)phenyl)piperidine DM29QLG Discovery agent N.A. Investigative [59]
4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine DMJNB8C Discovery agent N.A. Investigative [59]
4-(2-(4-fluorophenoxy)phenyl)piperidine DMFQT9O Discovery agent N.A. Investigative [59]
4-(2-(benzyloxy)-3-fluorophenyl)piperidine DMM2NHZ Discovery agent N.A. Investigative [59]
4-(2-(benzyloxy)-6-fluorophenyl)piperidine DMF3S50 Discovery agent N.A. Investigative [59]
4-(2-(benzyloxy)phenyl)piperidine DMOC7PY Discovery agent N.A. Investigative [59]
4-(2-(phenoxymethyl)phenyl)piperidine DM0OFRQ Discovery agent N.A. Investigative [59]
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine DMQUAP2 Discovery agent N.A. Investigative [60]
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine DMUBHRF Discovery agent N.A. Investigative [59]
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine DMJ2GW0 Discovery agent N.A. Investigative [59]
4-(2-fluoro-6-phenoxyphenyl)piperidine DMXIGWC Discovery agent N.A. Investigative [59]
4-(2-phenoxyphenyl)piperidine DMB5IFA Discovery agent N.A. Investigative [59]
4-(3'-furyl)-aniline DMZ1TNM Discovery agent N.A. Investigative [70]
4-(3-fluoro-2-phenoxyphenyl)piperidine DM1C3NZ Discovery agent N.A. Investigative [59]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [74]
6-(piperidin-4-ylmethoxy)-2-naphthonitrile DMBQKGY Discovery agent N.A. Investigative [49]
7-(piperidin-4-ylmethoxy)-2-naphthonitrile DM6I5K1 Discovery agent N.A. Investigative [49]
8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane DMOM4VS Discovery agent N.A. Investigative [71]
AMIFLAMINE DMJ0BEG Discovery agent N.A. Investigative [58]
Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine DM4D7V6 Discovery agent N.A. Investigative [75]
Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine DMTH4BG Discovery agent N.A. Investigative [76]
D-166A DMQJD4P Discovery agent N.A. Investigative [77]
D-211A DMIBOAK Discovery agent N.A. Investigative [77]
D-211B DM54CKZ Discovery agent N.A. Investigative [77]
D-254C DM6KFCO Discovery agent N.A. Investigative [77]
D-257A DMN7E6Y Discovery agent N.A. Investigative [77]
D-257C DM5GLJ2 Discovery agent N.A. Investigative [77]
Difluorobenztropine DM8ABD6 Discovery agent N.A. Investigative [72]
Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine DM293XH Discovery agent N.A. Investigative [78]
KF-A5 DMFBMYG Discovery agent N.A. Investigative [79]
MDL-28618 DMF76M8 Discovery agent N.A. Investigative [48]
METHYLENEDIOXYAMPHETAMINE DMP204G Discovery agent N.A. Investigative [80]
METHYLENEDIOXYMETHAMPHETAMINE DMYVU47 Discovery agent N.A. Investigative [81]
MMDA DMUWVGP Discovery agent N.A. Investigative [82]
N,N-dimethyl(2-phenoxyphenyl)methanamine DMWK91T Discovery agent N.A. Investigative [83]
N-(2-oxazolemethyl)milnacipran DMVGP02 Discovery agent N.A. Investigative [84]
N-benzyl-N-isobutylpiperidin-4-amine DM6QK7E Discovery agent N.A. Investigative [78]
N-desalkylquetiapine DMBFC1U Discovery agent N.A. Investigative [85]
NISOXETINE DMZBNH0 Discovery agent N.A. Investigative [86]
norzotepine DMS3N4X Discovery agent N.A. Investigative [87]
Para-chloroamphetamine DMOH75D Discovery agent N.A. Investigative [68]
PF-18298 DMJMU09 Discovery agent N.A. Investigative [52]
PF-3409409 DMEZA0T Attention deficit hyperactivity disorder 6A05.Z Investigative [88]
PF-526014 DMD8QOZ Discovery agent N.A. Investigative [52]
POLYGALATENOSIDE B DMUTV5P Discovery agent N.A. Investigative [89]
PTI-601 DMQUSXK Pain MG30-MG3Z Investigative [12]
PYROVALERONE DMV48S2 Discovery agent N.A. Investigative [61]
R-NORDULOXETINE DMGV4DS Discovery agent N.A. Investigative [53]
RTI-219 DM2QYXN Discovery agent N.A. Investigative [90]
S-34324 DMZLQ5W Discovery agent N.A. Investigative [91]
S33005 DM3Z6TI Depression 6A70-6A7Z Investigative [92]
TQ-1017 DMEF32D Pain MG30-MG3Z Investigative [93]
Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine DMEDC5I Discovery agent N.A. Investigative [76]
WAY-256805 DM48MC3 Pain MG30-MG3Z Investigative [94]
WIN-35066-2 DMOX1S0 N. A. N. A. Investigative [95]
[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine DM4BYEQ Discovery agent N.A. Investigative [62]
[3H]nisoxetine DMS3WNG Discovery agent N.A. Investigative [12]
[3H]WIN35428 DMI8RU0 Discovery agent N.A. Investigative [96]
{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine DM3FBAZ Discovery agent N.A. Investigative [97]
------------------------------------------------------------------------------------
⏷ Show the Full List of 173 Investigative Drug(s)

References

1 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
2 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
3 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
4 Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
5 Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
6 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
7 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
8 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
9 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
10 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
11 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
13 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
14 Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
15 Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16.
16 Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63.
17 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
18 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
19 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
20 Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
21 Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
24 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
25 The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27 Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
28 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
29 Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
30 Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6.
31 Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91.
32 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
33 Clinical pipeline report, company report or official report of BioInvent.
34 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
35 Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
36 Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6.
37 Company report (BioLineRx)
38 Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
39 Pfizer. Product Development Pipeline. March 31 2009.
40 Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9.
41 Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant
42 Clinical pipeline report, company report or official report of Neurosearch.
43 Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56.
44 Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
45 Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31.
46 Clinical pipeline report, company report or official report of Neurosearch.
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
48 Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
49 Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
50 Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
51 Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5.
52 Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
53 Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
54 Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
55 Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
56 N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
57 Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
58 Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
59 Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
60 Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
61 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
62 Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
63 Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
64 Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72.
65 Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
66 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
67 Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
68 Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
69 Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70.
70 Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
71 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
72 Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
73 Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104.
74 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
75 Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9.
76 Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
77 Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
78 N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
79 Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
80 Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31.
81 The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
82 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
83 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.
84 Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9.
85 N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant ... Neuropsychopharmacology. 2008 Sep;33(10):2303-12.
86 Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31.
87 Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81.
88 Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
89 Antidepressant principles of the roots of Polygala tenuifolia. J Nat Prod. 2006 Sep;69(9):1305-9.
90 Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
91 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
92 Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
93 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
94 Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem. 2008 Jul 10;51(13):4038-49.
95 Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9.
96 3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41.
97 Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(p... Bioorg Med Chem. 2009 Nov 15;17(22):7802-15.
98 Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
99 Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.
100 chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem. 2007 Jun 15;282(24):17837-44.